Detailed Narrative
Q3 FY25 Performance Overview
Neogen Chemicals delivered a strong Q3 FY25, with revenue growing 22% year-on-year to ₹201 crores. This growth was primarily driven by a 36% increase in organic revenue to ₹177 crores and healthy contributions from the recently merged BuLi Chem. EBITDA saw a significant 71% improvement, reaching ₹34.6 crores, resulting in a consolidated margin of 17.2%. Profit After Tax stood at ₹10 crores, benefiting from strong operational results and a favorable base effect from the previous year.
Battery Materials Expansion & Progress
The company is actively advancing its battery materials projects, having deployed ₹419 crores of the envisaged ₹1,500 crore CAPEX by Q3 FY25. The Greenfield battery materials facility (MUIS technology) is on track for commercial production in FY26, with 70% of civil and design work completed. New capacities of 400 MTPA for lithium electrolyte salts and additives and 2,000 MTPA for electrolyte at Dahej are progressing, with trial supplies already shipped to customers.
Revised Battery Chemicals Revenue Outlook
Neogen Chemicals revised its short-term revenue guidance for the battery chemicals business due to delays in Indian electrolyte demand and customer approvals. For FY25, the expected revenue from battery chemicals is now ₹20-30 crores (down from ₹50-75 crores). For FY26, the guidance has been adjusted to a range of ₹300-500 crores (from an earlier ₹450-500 crores), with more clarity expected in the next quarter's call.
Strategic Customer Engagements & Market Position
The company is engaging with 4-5 active international customers for electrolyte salts, who are keen to switch from Chinese suppliers and can potentially absorb the entire planned capacity of 2,500 MTPA (to be online by September 2025) and eventually 5,500 MTPA (by end of FY26). For electrolytes, the focus is on the domestic market (95% domestic target), with initial volumes from Dahej supporting smaller requirements and Pakhajan catering to larger, stabilized demands from giga factories.
BuLi Chemicals Integration & Growth
BuLi Chemicals India Private Limited officially merged with Neogen Chemicals effective January 31, 2025, streamlining operations and enhancing market position. BuLi Chem demonstrated significant progress, broadening its product offerings and commencing exports to EU, Korea, and Japan. The business is currently operating at full utilization in Q3 and Q4 FY25, with revenue expected to be in the ₹50-100 crore range for FY25, and projected to exceed ₹100 crore in FY26.
CSM Business and End-User Diversification
The Custom Synthesis Manufacturing (CSM) business contributed approximately 14% to overall revenue in 9 months FY25, fluctuating between 12-15% quarterly. Neogen aims to increase this contribution to 15-20% in FY26 by leveraging opportunities across pharma, agrochemicals, flavors & fragrances, industrial, and semiconductor applications. While advanced intermediates face challenges from Chinese dumping, other segments are performing well, supported by a China-Plus-One strategy.
Raw Material Pricing & Margin Management
Management noted that lithium and bromine raw material prices experienced a sharp decline year-on-year. However, the company's long-term contracts are formula-based, allowing for raw material price pass-through, which helps protect absolute EBITDA and ROCE. The FY26 standalone revenue guidance of ₹950-1,000 crores is based on normalized lithium and bromine prices, with an absolute EBITDA margin target of 18% +/- 1-1.5%.